These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 9698609)

  • 21. Prevalence of recurring BRCA mutations among Ashkenazi Jewish women with breast cancer.
    Robson M; Dabney MK; Rosenthal G; Ludwig S; Seltzer MH; Gilewski T; Haas B; Osborne M; Norton L; Gilbert F; Offit K
    Genet Test; 1997; 1(1):47-51. PubMed ID: 10464625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The founder mutations in the BRCA1, BRCA2, and ATM genes in Moroccan Jewish women with breast cancer.
    Kreiss Y; Barak F; Baruch RG; Levy-Lahad E; Pras E; Friedman E
    Genet Test; 2000; 4(4):403-7. PubMed ID: 11216667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families.
    Tonin P; Weber B; Offit K; Couch F; Rebbeck TR; Neuhausen S; Godwin AK; Daly M; Wagner-Costalos J; Berman D; Grana G; Fox E; Kane MF; Kolodner RD; Krainer M; Haber DA; Struewing JP; Warner E; Rosen B; Lerman C; Peshkin B; Norton L; Serova O; Foulkes WD; Garber JE
    Nat Med; 1996 Nov; 2(11):1179-83. PubMed ID: 8898735
    [No Abstract]   [Full Text] [Related]  

  • 24. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An unaffected individual from a breast/ovarian cancer family with germline mutations in both BRCA1 and BRCA2.
    Moslehi R; Russo D; Phelan C; Jack E; Antman K; Narod S
    Clin Genet; 2000 Jan; 57(1):70-3. PubMed ID: 10733239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes.
    Friedman E; Bar-Sade Bruchim R; Kruglikova A; Risel S; Levy-Lahad E; Halle D; Bar-On E; Gershoni-Baruch R; Dagan E; Kepten I; Peretz T; Lerer I; Wienberg N; Shushan A; Abeliovich AD
    Am J Hum Genet; 1998 Oct; 63(4):1224-7. PubMed ID: 9758598
    [No Abstract]   [Full Text] [Related]  

  • 28. High frequency of recurrent mutations in BRCA1 and BRCA2 genes in Polish families with breast and ovarian cancer.
    Grzybowska E; Zientek H; Jasinska A; Rusin M; Kozlowski P; Sobczak K; Sikorska A; Kwiatkowska E; Gorniak L; Kalinowska E; Utracka-Hutka B; Wloch J; Chmielik E; Krzyzosiak WJ
    Hum Mutat; 2000 Dec; 16(6):482-90. PubMed ID: 11102977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A family with three germline mutations in BRCA1 and BRCA2.
    Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
    Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High frequency of BRCA1 and BRCA2 germline mutations in Ashkenazi Jewish ovarian cancer patients, regardless of family history.
    Beller U; Halle D; Catane R; Kaufman B; Hornreich G; Levy-Lahad E
    Gynecol Oncol; 1997 Nov; 67(2):123-6. PubMed ID: 9367693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The APC I1307K allele and BRCA-associated ovarian cancer risk.
    Maresco DL; Arnold PH; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Boyd J
    Am J Hum Genet; 1999 Apr; 64(4):1228-30. PubMed ID: 10090911
    [No Abstract]   [Full Text] [Related]  

  • 32. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
    Ganguly T; Dhulipala R; Godmilow L; Ganguly A
    Hum Genet; 1998 May; 102(5):549-56. PubMed ID: 9654203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A; Dekel E; Chetrit A; Lerner-Geva L; Bar-Am A; Beck D; Beller U; Ben-Baruch G; Piura B; Friedman E; Struewing JP; Modan B
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of BRCA1 and BRCA2 mutations in Hungarian families with breast or breast-ovarian cancer.
    Ramus SJ; Kote-Jarai Z; Friedman LS; van der Looij M; Gayther SA; Csokay B; Ponder BA; Olah E
    Am J Hum Genet; 1997 May; 60(5):1242-6. PubMed ID: 9150174
    [No Abstract]   [Full Text] [Related]  

  • 36. BRCA1 and BRCA2 in breast cancer families from Wales: moderate mutation frequency and two recurrent mutations in BRCA1.
    Lancaster JM; Carney ME; Gray J; Myring J; Gumbs C; Sampson J; Wheeler D; France E; Wiseman R; Harper P; Futreal PA
    Br J Cancer; 1998 Dec; 78(11):1417-20. PubMed ID: 9836472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 and BRCA2 testing: weighing the demand against the benefits.
    Devilee P
    Am J Hum Genet; 1999 Apr; 64(4):943-8. PubMed ID: 10090879
    [No Abstract]   [Full Text] [Related]  

  • 38. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing.
    Rubin SC; Blackwood MA; Bandera C; Behbakht K; Benjamin I; Rebbeck TR; Boyd J
    Am J Obstet Gynecol; 1998 Apr; 178(4):670-7. PubMed ID: 9579428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals.
    Berman DB; Costalas J; Schultz DC; Grana G; Daly M; Godwin AK
    Cancer Res; 1996 Aug; 56(15):3409-14. PubMed ID: 8758903
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families.
    Machácková E; Foretová L; Navrátilová M; Valík D; Claes K; Messiaen L
    Cas Lek Cesk; 2000 Oct; 139(20):635-7. PubMed ID: 11192759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.